OPDP Says TV Ad is Out of Bounds with Fourth Untitled Letter of 2024
The FDA Law Blog
SEPTEMBER 17, 2024
By Sarah Wicks & Dara Katcher Levy — FDA’s Office of Prescription Drug Promotion (OPDP) has issued its fourth Untitled Letter of 2024 – this one to AbbVie, Inc. The approved labeling for UBRELVY includes a warning and precaution regarding hypersensitivity reactions, with the most common adverse reactions being nausea and somnolence.
Let's personalize your content